Pilnik Richard D. Form 3 DiaMedica Therapeutics / Richard D. Pilnik ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Pilnik Richard D.

(Last) (First) (Middle)

2 CARLSON PARKWAY

SUITE 260

(Street)

MINNEAPOLIS MN 55447

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/06/2018

3. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Voting Common Shares, no par value per share	17,588(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	10/06/2021	Voting Common Shares	1,250	17.31(3)	D
Stock Option (right to buy)	(4)	05/09/2022	Voting Common Shares	1,250	25.58(3)	D
Stock Option (right to buy)	(5)	10/31/2022	Voting Common Shares	1,250	24.98(3)	D
Stock Option (right to buy)	(6)	06/25/2023	Voting Common Shares	1,250	16.1(3)	D
Stock Option (right to buy)	(7)	11/06/2023	Voting Common Shares	1,250	12.94(3)	D
Stock Option (right to buy)	(8)	07/07/2024	Voting Common Shares	7,500	10.38(3)	D
Stock Option (right to buy)	(9)	12/01/2025	Voting Common Shares	24,000	2.26(3)	D
Stock Option (right to buy)	(10)	11/28/2026	Voting Common Shares	10,000	3.91(3)	D
Stock Option (right to buy)	(11)	06/19/2027	Voting Common Shares	5,000	4.82(3)	D
Stock Option (right to buy)	(12)	04/17/2028	Voting Common Shares	6,000	8.43(3)	D

Explanation of Responses:

1. Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.

2. This stock option vests in 12 equal quarterly installments over three years starting on January 6, 2012.

3. Represents the conversion of the exercise price from CAD$ to US$ on November 30, 2018.

4. This stock option vests in 12 equal quarterly installments over three years starting on August 9, 2012.

5. This stock option vests in 12 equal quarterly installments over three years starting on January 31, 2013.

6. This stock option vests in 12 equal quarterly installments over three years starting on September 25, 2013.

7. This stock option vests in 12 equal quarterly installments over three years starting on February 6, 2014.

8. This stock option vests in 12 equal quarterly installments over three years starting on October 7, 2014.

9. This stock option vests in 12 equal quarterly installments over three years starting on March 1, 2016.

10. This stock option vests in 12 equal quarterly installments over three years starting on February 28, 2017.

11. This stock option vests in 12 equal quarterly installments over three years starting on September 19, 2017.

12. This stock option vests in 12 equal quarterly installments over three years starting on July 17, 2018.

	/s/ Amy Culbert, attorney-in-fact	12/06/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.